DRR168513
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.390
- PANCREAS_BETA_CELLS+0.360
- ESTROGEN_RESPONSE_LATE+0.350
- FATTY_ACID_METABOLISM+0.290
- SPERMATOGENESIS+0.280
- G2M_CHECKPOINT+0.260
- CHOLESTEROL_HOMEOSTASIS+0.230
- ESTROGEN_RESPONSE_EARLY+0.220
- BILE_ACID_METABOLISM+0.210
- XENOBIOTIC_METABOLISM+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.450
- TGF_BETA_SIGNALING-0.420
- HEDGEHOG_SIGNALING-0.380
- WNT_BETA_CATENIN_SIGNALING-0.380
- APICAL_JUNCTION-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- NOTCH_SIGNALING-0.290
- ANGIOGENESIS-0.280
- MYC_TARGETS_V2-0.280
- INTERFERON_GAMMA_RESPONSE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311166 | — | — | 0.717 |
| 2 | EPT0562 | EPN | EPN Tumor | 0.710 |
| 3 | R286 | — | — | 0.695 |
| 4 | TCGA-BB-4227-01A-01R-1873-07 | — | — | 0.686 |
| 5 | TCGA-B6-A0IA-01A-11R-A034-07 | — | B | 0.683 |
| 6 | DRR168581 | — | — | 0.679 |
| 7 | GSM5359440 | — | — | 0.677 |
| 8 | SRR23303742 | — | — | 0.672 |
| 9 | SRR2932844 | — | — | 0.672 |
| 10 | SRR2932846 | — | — | 0.667 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |